UroStream

From November 4–10, 2024, the 8th West China Uro-Oncology Tianfu Academic Conference and the 10th Urological and Male Reproductive Oncology Annual Conference of the Sichuan Anti-Cancer Association were successfully held in Chengdu. This event shared the latest domestic and international advancements in clinical data, research findings, complex case discussions, and cutting-edge diagnostics and treatment. Following the conference, Oncology Frontier invited the conference chair, Dr. Qiang Wei from West China Hospital of Sichuan University, to discuss the highlights of the event, the development of urological oncology in China, and the value of multidisciplinary treatment (MDT).

Editor’s Note: Comprehensive and accurate assessment of prostate cancer metastasis and diagnosis is crucial for adjusting treatment plans and evaluating prognosis. With continuous advancements in diagnostic and therapeutic technologies, novel…

The 2024 European Society for Medical Oncology (ESMO) Congress was held from September 13 to 17 in Barcelona, Spain. During the event, multiple key studies in urologic oncology were highlighted. Dr. Dingwei Ye from Fudan University Shanghai Cancer Center presented preliminary findings on the safety, tolerability, and efficacy of BL-B01D1, a novel EGFR/HER3 dual-targeting antibody-drug conjugate (ADC), in patients with previously treated metastatic urothelial carcinoma (UC), garnering considerable attention. Urology Frontier invited Dr. Dingwei Ye to share major developments in urologic oncology from the congress, discuss new dual-targeted therapies for advanced UC, and highlight the Fudan University Shanghai Cancer Center’s progress in this area.

For most prostate cancer patients, resistance to androgen deprivation therapy (ADT) inevitably develops within 18-36 months, progressing to castration-resistant prostate cancer (CRPC). This transition not only increases mortality risk but also poses a serious challenge to survival outcomes. The European Society for Medical Oncology (ESMO) Annual Meeting 2024, held from September 13 to 17 in Barcelona, Spain, showcased numerous studies on metastatic castration-resistant prostate cancer (mCRPC). Oncology Frontier - Urology Insight invited Dr. Xiaojie Bian from Fudan University Shanghai Cancer Center to share the latest advances.

Surgical treatment is a crucial approach for prostate cancer, with radical prostatectomy being the gold standard. Even for intermediate and advanced prostate cancer, surgery can offer the possibility of clinical cure. For rare subtypes and complex cases, decisions often require multidisciplinary team (MDT) discussions and thorough communication with the patient. During the recent CSCO Annual Meeting, Urology Frontier invited Dr. Jianming Guo from Zhongshan Hospital, Fudan University, to share insights on the current state of prostate cancer diagnosis and treatment in China, recent research results, the standardized development of MDT, and the future directions for the urology team.

Radical nephroureterectomy (RNU) remains the gold standard treatment for upper tract urothelial carcinoma (UTUC). However, some patients with a solitary kidney or insufficient renal reserve may require alternative approaches to preserve kidney function. In recent years, advancements in systemic drug therapy and various endoscopic focal treatment techniques have provided kidney-sparing options for such patients. Nonetheless, large-scale case reports or prospective studies remain scarce. At the 31st Urology Academic Conference (CUA 2024), organized by the Chinese Medical Association and the Chinese Urological Association, Dr. Qiang Wei and  Yige Bao from West China Hospital, Sichuan University, presented their report on multimodal kidney-sparing treatment in 62 patients with high-risk localized UTUC.

Radical nephrectomy combined with venous tumor thrombus resection is the preferred treatment for renal cell carcinoma (RCC) with inferior vena cava tumor thrombus (IVC-TT) and can significantly improve patient prognosis. Preoperative neoadjuvant therapy aimed at reducing tumor thrombus level and grade is of great importance in reducing perioperative risks. Recently, the NEOTAX study, led by Academician Xu Zhang, Professor Xin Ma, and Professor Liangyou Gu from the Chinese People's Liberation Army General Hospital, was presented at the ESMO Congress (1701P). The study demonstrated that the neoadjuvant regimen of toripalimab combined with axitinib reduced tumor thrombus levels in 96.0% of RCC patients with IVC-TT and achieved thrombus downstaging in 44% of patients, thereby simplifying the surgical process. The study results were published in the Nature sub-journal Signal Transduction and Targeted Therapy (IF: 40.8). The combined treatment showed significant efficacy in reducing IVC-TT and improving surgical feasibility, offering a new direction for improving the prognosis of such patients. Below are the study details.

Surgery is a fundamental treatment for renal cancer, particularly for patients with stage I and II cancers, where surgery can cure the majority of cases and ensure long-term survival. At the 2024 CSCO Annual Meeting, Urology Frontier invited Dr. Pei Dong from Sun Yat-sen University Cancer Center to discuss this year’s key updates in the CSCO guidelines for surgical treatment of renal cancer, comparisons between single-port and traditional laparoscopic nephrectomy, and the role of neoadjuvant therapy in enhancing surgical outcomes.

Prostate cancer is a common malignant tumor in elderly men. However, with continuous advancements in diagnostic and treatment strategies, patient survival rates have improved, and patient-centered care has become a key focus in oncology. During the recent CUA Annual Meeting, Urology Frontier invited Dr. Eamonn Rogers from the National University of Ireland to share his thoughts on the future of prostate cancer research, the importance of patient-reported outcomes (PROs), and evolving models of care to meet modern medical challenges.